Patents by Inventor Roland Drews

Roland Drews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7989654
    Abstract: The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterized in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: August 2, 2011
    Assignee: UCB Pharma GmbH
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Patent number: 7985873
    Abstract: The present invention provides a process for the production of a compound of formula (I) or a salt thereof, wherein R is hydrogen, a straight, branched or cyclic C1-C6 alkyl group or an aryl group which may optionally be substituted. This process comprises: (a) reacting a compound of formula (II), with a compound of formula (III), wherein R is as defined above and X is a leaving group, in the presence of N,N-di-isopropylethylamine.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: July 26, 2011
    Assignee: UCB Pharma GmbH
    Inventors: Seth C. Ennis, Roland Drews, Claus Meese
  • Patent number: 7919117
    Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: April 5, 2011
    Assignee: UCB Pharma GmbH
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Publication number: 20100168459
    Abstract: The present invention provides a process for the production of a compound of formula (I) or a salt thereof, wherein R is hydrogen, a straight, branched or cyclic C1-C6 alkyl group or an aryl group which may optionally be substituted. This process comprises: (a) reacting a compound of formula (II), with a compound of formula (III), wherein R is as defined above and X is a leaving group, in the presence of N,N-di-isopropylethylamine.
    Type: Application
    Filed: June 5, 2007
    Publication date: July 1, 2010
    Applicant: SCHWARZ PHARMA LTD.
    Inventors: Seth C. Ennis, Roland Drews, Claus Meese
  • Patent number: 7670621
    Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.
    Type: Grant
    Filed: April 3, 2004
    Date of Patent: March 2, 2010
    Assignee: Schwarz Pharma AG
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Publication number: 20090274761
    Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.
    Type: Application
    Filed: April 2, 2009
    Publication date: November 5, 2009
    Applicant: SCHWARZ PHARMA AG
    Inventors: Armin BREITENBACH, Claus MEESE, Hans-Michael WOLFF, Roland DREWS
  • Publication number: 20090012159
    Abstract: The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterised in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments.
    Type: Application
    Filed: June 18, 2008
    Publication date: January 8, 2009
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Publication number: 20060029673
    Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3 alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.
    Type: Application
    Filed: April 3, 2004
    Publication date: February 9, 2006
    Applicant: Schwarz Pharma AG
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Publication number: 20060014832
    Abstract: The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterised in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments.
    Type: Application
    Filed: April 3, 2004
    Publication date: January 19, 2006
    Applicant: Schwarz Pharma AG
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews